Detalle Publicación

ARTÍCULO

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

Autores: Bellmunt, J; González-Larriba, JL; Prior Darbonnens, Celia; Maroto, P; Carles, J; Castellano, D; Mellado, B; Gallardo, E; Pérez Gracia, José Luis; Aguilar, G; Villanueva, X; Albanell, J; Calvo González, Alfonso

Título de la revista: ANNALS OF ONCOLOGY

ISSN: 0923-7534

Volumen: 22

Número: 12

Páginas: 2646-2653

Fecha de publicación: 2011

DOI: https://doi.org/10.1093/annonc/mdr023.

Impacto:

Google Scholar